**Study Overview**: This study aims to assess the safety and effectiveness of a medicine called human menopausal gonadotropin (hMG), which is used to help develop multiple follicles (tiny sacs in the ovaries that contain eggs) in women facing infertility. The purpose is to see if hMG can help increase the chances of pregnancy and having a baby when used in Assisted Reproductive Technology (ART), such as in vitro fertilization (IVF). **Key Points**: - **Participation Requirements**: Women aged 18-42, with certain health conditions, might be eligible. Participants should be willing to undergo up to two ovarian stimulation cycles and self-administer medications. - **Study Details**: This trial involves taking hMG and possibly a placebo (inactive substance) in a controlled setting. It is a double-blind trial, meaning neither the participants nor the researchers know who receives the hMG or placebo. - **Risks and Benefits**: As with any medical study, there could be side effects or risks. Participants should discuss these with their healthcare provider to weigh the potential benefits and risks before joining the study. **Eligibility**: Women must meet certain health criteria, such as having regular menstrual cycles and normal hormone levels. Some conditions, like untreated hormonal disorders or a history of certain medical treatments, may lead to exclusion.